ICA-100

Project "ICA-100" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Blood pressure follow-up is essential in managing hemodynamically unstable patients at Intensive Care Units (ICU). Traditionally, mercury sphygmomanometers have been used for this purpose, and are regarded as the gold standard for Blood Pressure measurement. Despite the relative simplicity of the technique, sphygmomanometers have obvious limitations regarding accuracy and tracking capability, especially crucial for hospital patients. In the most critical patients the invasive arterial line catheter must be used, which however poses serious risks for severe complications. Over the past decades, several attempts have been undertaken to develop an effective, accurate and reliable solutions to continuously monitor blood pressure in a non-invasive way. Hitherto, none of the solutions under development have achieved a massive market deployment. Major obstacles for the implementation of state-of-the-art solutions are related to their limited performance, resulting in poor accuracy in hypo/hyper tension episodes, influence of patient movements on the system response, and need for periodic and frequent recalibrations. ICARIA has developed a solution for blood pressure monitoring (ICA-100) based on a novel operating principle that allows obtaining an accurate diastolic and systolic Blood Pressure read-out. The ICA-100 has already been validated in healthy volunteers (TRL5). The technology is protected by two international patents, granting ICARIA freedom-to-operate. In the frame of this Phase 1 Project we aim to further develop our marketing strategy and financial plan. Besides, we aim to assess thoroughly the relevant regulatory and legal framework for the Project. After completing this feasibility study, we plan to develop and commercialise a certified device for Continuous Non-Invasive Blood Pressure monitoring. Having a positive impact in 655m hospital patients and a potential favourable effect on 1.3b hypertensive individuals, from which only 1 in 5 is under control.